Citizens JMP Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

In a report released today, Silvan Tuerkcan from Citizens JMP reiterated a Buy rating on Taysha Gene Therapies, with a price target of $6.00. The company’s shares closed last Friday at $4.88.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Tuerkcan is a 4-star analyst with an average return of 7.6% and a 42.47% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Solid Biosciences, and Exelixis.

In addition to Citizens JMP, Taysha Gene Therapies also received a Buy from Truist Financial’s Joon Lee in a report issued on October 10. However, on October 3, TR | OpenAI – 4o reiterated a Hold rating on Taysha Gene Therapies (NASDAQ: TSHA).

TSHA market cap is currently $1.33B and has a P/E ratio of -13.67.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSHA in relation to earlier this year. Most recently, in August 2025, Sukumar Nagendran, the President and Head of R&D of TSHA sold 57,054.00 shares for a total of $162,603.90.